Fig. 6: PMN-MDSC depletion enhances efficacy of anti-PD-L1 treatment. | Cell Death & Disease

Fig. 6: PMN-MDSC depletion enhances efficacy of anti-PD-L1 treatment.

From: Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs

Fig. 6

a Expression of genes that have been implicated in MDSC expansion quantified by real-time PCR. *p < 0.05; **p < 0.01; ***p < 0.001. b The ratio of CD11b+Ly6G+ cells in the bone marrow, lungs and primary tumour sites determined by flow cytometry was shown. Mice were subcutaneously coinjected by LLCs and BMSCs. Tumour-bearing mice were treated with CXCL5 antibody, GM-CSF antibody or iNOS antagonist 1400 W, respectively, or combined with anti-PD-L1 antibody. c The ratio of CD11b + Ly6G + cells in the bone marrow, lungs or primary tumour sites was presented in column bar chart. Data were presented as the mean ± SD and analyzed with Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001. d Kaplan–Meier survival curve for overall survival of mice with co-injection of BMSCs and LLC. Tumour-bearing mice were treated with PD-L1 antibody combined with CXCL5 antibody, 1400 W or GM-CSF antibody, respectively. e Proposed working model of BMSCs in different site of tumour-bearing mice.

Back to article page